The antitumor effect of trabectedin (TR) is potentiated by olaparib (OL) in preclinical models of bone and soft tissue sarcomas (STS).

被引：0
|
作者：
Pignochino, Ymera [1 ]
Capozzi, Federica [2 ]
Dell'aglio, Carmine [2 ]
Basirico, Marco [2 ]
D'ambrosio, Lorenzo [2 ]
Galizia, Danilo [2 ]
Palesandro, Erica [2 ]
Benassi, Maria Serena [3 ]
Aglietta, Massimo [2 ]
Grignani, Giovanni [4 ]
机构：
[1] Univ Turin, Fdn Piemonte Oncol, Candiolo, Italy
[2] Univ Turin, Candiolo, Italy
[3] Ist Ortoped Rizzoli, Bologna, Italy
[4] FPO, Candiolo, Italy
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-LB-213
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB213
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Combinatorial effects of a sequence of trabectedin (T) and CD13-targeted tissue factor tTF-NGR on human vascular endothelial cells (HUVEC) and in soft tissue sarcoma (STS) models
    Brand, Caroline
    Pavelka, Stefanie
    Hessling, Kathrin
    Hintelmann, Heike
    Berdel, Andrew F.
    Baumer, Sebastian
    Baumer, Nicole
    Lenz, Georg
    Schliemann, Christoph
    Berdel, Wolfgang E.
    Schwoppe, Christian
    CANCER RESEARCH, 2024, 84 (06)
  • [42] Geriatric assessment of elderly chemotherapy-naive patients treated with trabectedin for advanced soft tissue sarcomas (STS): The E-TRAB study of the German Interdisciplinary Sarcoma Group (GISG-13)
    Kasper, B.
    Reichardt, P.
    Schuler, M.
    Hohenberger, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] Prognostic/predictive biomarkers in advanced soft tissue sarcomas (STS): Translational research associated to randomized phase II trial comparing trabectedin-doxorubicin versus doxorubicin-A GEIS study.
    Martin Broto, Javier
    Martinez-Serra, Jorge
    Ramos, Rafael
    Antonio Lopez-Guerrero, Jose
    Bague, Silvia
    Martinez, Carmen
    Alvarez, Ramiro
    Garcia del Muro, Xavier
    De Las Penas, Ramon
    Gutierrez, Antonio
    Martinez-Trufero, Javier
    Cruz, Josefina
    Poveda, Andres
    Maria Alvarez, Rosa
    Cubedo, Ricardo
    Redondo, Andrs
    Maurel, Juan Oppor
    Angeles Sala, Maria
    Lopez-Martin, Jose A.
    Lopez-Pousa, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Effect of high-dose ifosfamide in advanced soft tissue sarcomas.: A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group
    Nielsen, OS
    Judson, I
    van Hoesel, Q
    le Cesne, A
    Keizer, HJ
    Blay, JY
    van Oosterom, A
    Radford, JA
    Svancárová, L
    Krzemienlecki, K
    Hermans, C
    van Glabbeke, M
    Oosterhuis, JW
    Verweij, J
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (01) : 61 - 67
  • [45] ANTITUMOR EFFECT OF TELOMERASE-SPECIFIC ONCOLYTIC ADENOVIRUS ON HUMAN BONE AND SOFT TISSUE SARCOMA CELLS
    Tazawa, Hiroshi
    Sasaki, Tsuyoshi
    Hasei, Jo
    Hashimoto, Yuuri
    Urata, Yasuo
    Ozaki, Toshifumi
    Fujiwara, Toshiyoshi
    JOURNAL OF GENE MEDICINE, 2014, 16 (7-8): : 261 - 262
  • [46] Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses
    Burgess, Melissa Amber
    Bolejack, Vanessa
    Van Tine, Brian Andrew
    Schuetze, Scott
    Hu, James
    D'Angelo, Sandra P.
    Attia, Steven
    Priebat, Dennis A.
    Okuno, Scott H.
    Riedel, Richard F.
    Davis, Lara Emily
    Mowa, Sujana
    Reed, Damon R.
    Butterfield, Lisa Helene
    Roszik, Jason
    Reinke, Denise K.
    Baker, Laurence H.
    Maki, Robert G.
    Patel, Shreyaskumar
    Tawbi, Hussein Abdul-Hassan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] C-reactive protein (CRP) and peripheral blood monocyte count (PBMC) in patients (pts) with advanced soft tissue sarcomas (ASTS) treated with trabectedin (TR): correlation with progression-free survival (PFS).
    Galizia, Danilo
    Boccone, Paola
    Miano, Sara
    Palesandro, Erica
    D'Ambrosio, Lorenzo
    Tolomeo, Francesco
    Aliberti, Sandra
    Bertotto, Ilaria
    Gatti, Marco
    Manca, Antonio
    Aglietta, Massimo
    Grignani, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Prexasertib (LY2606368) is highly active as a monotherapy or in combination with chemotherapy in preclinical models of pediatric bone and soft tissue sarcoma
    Lowery, D.
    Blosser, Wayne
    Dowless, Michele
    Renschler, Matthew
    Stephens, Jennifer
    Beckmann, Richard
    Stancato, Louis
    CANCER RESEARCH, 2018, 78 (19)
  • [49] A non-randomized, open-label phase II trial evaluating efficacy and feasibility of combined treatment with trabectedin and nivolumab in patients with metastatic or inoperable soft tissue sarcomas (STS) after failure of an anthracycline-containing regimen
    Mueller, D. W.
    Reichardt, P.
    Gruenwald, V.
    Kasper, B.
    Wardelmann, E.
    Schmidt, C. A.
    Walker, M.
    Decker, S. G.
    Al-Batran, S-E.
    Pink, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S991 - S991
  • [50] Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Preliminary results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc) for the non-L sarcoma cohort.
    Pink, Daniel
    Andreou, Dimosthenis
    Florcken, Anne
    Golf, Alexander
    Richter, Stephan
    Kessler, Torsten
    Kortum, Martin
    Schmidt, Christian Andreas
    Kasper, Bernd
    Wardelmann, Eva
    Bahr, Jeanette
    Mueller, Daniel Wilhelm
    Sookthai, Disorn
    Al-Batran, Salah-Eddin
    Reichardt, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345